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covariates), showed 6-month depression and poorer func-
tional QoL predicting mortality, as did 6–12 month increases 
in anxiety and 6–12 month decreases in physical and func-
tional QoL. Multivariate analyses using all PROs showed 
independent prediction by 6-month depression and decreas-
ing QoL over 6–12 months and 12–24 months. Elevated 
depression scores six months post-diagnosis constituted an 
increased mortality risk. Early intervention for depressive 
symptoms may reduce mortality.
Keywords Cancer · Mortality · Patient reported 
outcomes · Anxiety · Depression · Quality of life
Introduction
Patient reported outcomes (PROs) are subjective measures 
of physical and psychological health. A range of PROs 
assessed either after diagnosis or during or after primary 
cancer treatment have been shown to predict patient mortal-
ity independently of demographic and clinical prognostic 
variables (Efficace, et al., 2021; Nakaya, 2014).1 System-
atic reviews show that higher self-reported depression and 
anxiety predict increased mortality across a range of cancers 
(Pinquart & Duberstein, 2010a; Wang, et al., 2020). Primary 
studies have found that self-reported physical symptoms 
(McFarland et al., 2020), fear of cancer recurrence (Kim, 
et al., 2020), and poorer quality of life (QoL) (Groenvold, 
et al., 2007; Quinten, et al., 2009; Ratjen, et al., 2018) also 
predict mortality.
Two proposed mechanisms link PROs to mortality. First, 
poorer PROs may be associated with higher psychological 
Abstract A number of patient-reported outcomes (PROs) 
predict increased mortality after primary cancer treatment. 
Studies, though, are sometimes affected by methodological 
limitations. They often use control variables that poorly pre-
dict life expectancy, examine only one or two PROs thus not 
controlling potential confounding by unmeasured PROs, and 
observe PROs at only a single point in time. To predict all-
cause mortality, this study used control variables affording 
good estimates of life expectancy, conducted multivariate 
analyses of multiple PROs to identify independent predic-
tors, and monitored PROs two years after diagnosis. We 
recruited a consecutive sample of 824 patients with uveal 
melanoma between April 2008 and December 2014. PROs 
were variables shown to predict mortality in previous stud-
ies; anxiety, depression, visual and ocular symptoms, visual 
function impairment, worry about cancer recurrence, and 
physical, emotional, social and functional quality of life 
(QoL), measured 6, 12 and 24 months after diagnosis. We 
conducted Cox regression analyses with a census date of 
December 2018. Covariates were age, gender, marital and 
employment status, self-reported co-morbidities, tumor 
diameter and thickness, treatment modality and chromo-
some 3 mutation status, the latter a genetic mutation strongly 
associated with mortality. Single predictor analyses (with 
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stress, which contributes to chronically heightened physi-
ological stress responses causing hypothalamic–pitui-
tary–adrenal (HPA) axis dysregulation and corticosteroid 
overproduction (Pinquart & Duberstein, 2010a). These lead 
to mortality through immune suppression and vascular and 
organ damage (Spiegel & Giese-Davis, 2003). The second 
mechanism is unhealthy behavior. Poorer PROs have been 
linked to poorer compliance with clinical advice, such as 
medication use and screening attendance, and poorer health 
behaviors such as unhealthy eating (Strine, et al., 2008).
Previous studies linking PROs to mortality are poten-
tially subject to confounds. First, PROs can co-vary with 
biomedical attributes, such as cancer progression, which are 
often difficult to measure but may nonetheless represent the 
true causes of mortality (Pinquart & Duberstein, 2010a). 
Most cancer mortality studies control for the effects of can-
cer site, stage and treatment, but these variables are often 
only poor or moderate prognostic indicators (Hui, 2015). 
More stringent hypothesis testing requires control variables 
that are stronger prognostic indicators. A second poten-
tial confound arises because most previous studies predict 
mortality from only one or two PROs. Many PROs, such as 
anxiety, depression, experience of symptoms, fear of cancer 
and QoL, appear to be strongly correlated (Brown, Fisher, 
Hope-Stone, Hussain, Heimann, et al., 2020). Studies that 
assess multiple predictors often show that good univariate 
predictors are not multivariate predictors because they share 
predictive variance with other PROs (Sehlen, et al., 2012; 
Walker, et al., 2020). Thus, existing studies linking PROs to 
mortality may be confounded by other, unmeasured, PROs, 
and it is unclear which PROs are most likely to contribute 
to mortality. A more precise understanding of relationships 
between PROs and mortality can be achieved by identifying 
PROs that predict mortality independently of others, thus 
strengthening (although not proving) causal claims. Thus, 
it is important to examine multiple PROs simultaneously 
using multivariate techniques, with appropriate prognostic 
controls, to identify independent predictors.
Third, many studies measure PROs at a single timepoint, 
usually at diagnosis or during or after primary treatments 
such as surgery. However, PROs change over time (Brown, 
et al., 2020), and it is unclear whether a single timepoint can 
entirely represent PROs over the full survivorship period. 
Anxiety and depression, for example, can be elevated 
immediately after diagnosis but reduce within three to six 
months (Beesley, et al., 2020; Crane, et al., 2019), whilst 
post-treatment physical symptoms and functional impair-
ments can worsen (Brown, et al., 2020). Documenting PROs 
at multiple timepoints can provide a more trustworthy rep-
resentation of patients’ experiences in survivorship. A sec-
ond advantage of multiple timepoints is the ability to assess 
impacts of temporal changes in individuals’ PROs. Repeated 
observation studies show temporal variability in associations 
with mortality (Eldridge, et al., 2019; Raffel, et al., 2017; 
Zhu, et al., 2020), suggesting that the timeframes of eleva-
tions in PROs might influence mortality. This would have 
implications for the timing of interventions.
Current study
We aimed to examine associations between mortality and 
PROs, similar to those used in previous studies, whilst 
addressing the above methodological limitations. We used 
uveal melanoma (UM) patients because strong prognostic 
indicators are available. UM has about a 50% ten-year mor-
tality rate, mostly attributable to metastatic disease which 
occurs most commonly in the liver (Kujala et al., 2003). Risk 
of metastatic disease is principally determined by tumor size 
and a single chromosomal mutation, monosomy 3, which 
itself is strongly associated with tumor size (Damato et al., 
2010). Using M3 status and tumor characteristics, prognos-
tication of life expectancy is sufficiently accurate to pro-
vide reliable individual estimates (DeParis, et al., 2016). 
We added M3 status and tumor diameter and thickness to 
control variables similar to those used in previous studies.
PROs in this study were anxiety and depression, visual 
and ocular symptoms, functional limitations, worry about 
recurrence (WREC) and physical, emotional, social and 
functional quality of life (QoL). We examined univariate 
relationships, predicting mortality from each PRO sepa-
rately, to assess whether these predicted mortality indepen-
dently of control variables only. We then used multivariate 
analyses, using all PROs as predictors, to assess which PROs 
predicted mortality independently of both control variables 
and other PROs. Instead of a single time point, we measured 
participants’ PROs over two years, at 6, 12 and 24 months 
after diagnosis. If worsening of individuals’ PRO scores 
between two timepoints, relative to the remainder of the 
sample, predicts mortality (controlling PRO scores at the 
first timepoint) this would indicate that mortality might be 
influenced by these changes.2
Poorer PROs are indicated by higher scores for anxi-
ety, depression, visual/ocular symptoms, visual function 
limitations, worry about cancer recurrence, and by lower 
QoL scores. We hypothesized that higher mortality would 
be independently predicted by poorer initial PRO scores 
six months after diagnosis. We predicted higher mortality 
in participants whose scores deteriorated, relative to the 
remainder of the sample, between 6–12 and 12–24 months.
2 Change is indicated by significant 12 or 24-month variables. Rela-
tive worsening or improvement does not necessarily connate change 
in absolute values, as, for example, an individual may show relative 
deterioration even if their scores remain stable if the rest of the sam-
ple improves at a greater rate.
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Method
Data were obtained from an audit of PROs, approved by the 
Liverpool Central Ethics Committee (03/06/072/A). Con-
secutive eligible patients were posted reply-paid question-
naires 6, 12 and 24 months after diagnosis. Inclusion criteria 
were: adult patients, aged 18 years and over, resident in Eng-
land or Wales, treated for posterior (choroid or ciliary body) 
UM at the Liverpool Ocular Oncology Centre (LOOC) 
between April 1st 2008 and December 31st 2014. Treat-
ment was based on the protocol described in Damato and 
Heimann (2013). Ruthenium plaque radiotherapy or proton 
beam radiotherapy were first considered. If the tumor was 
unsuitable for radiotherapy, patients underwent trans-scleral 
local resection, trans-retinal endoresection or enucleation 
(eye removal). Prognostic testing to determine M3 status 
was offered and explained to patients, who chose whether 
to undergo prognostication. Prognostic outcomes were 
provided before the six-month observation, and explained 
to patients by LOOC staff or their clinical oncology team. 
Patients with a poor prognosis were given the option to 
attend a regular liver screening program.
Measures
Demographic, clinical and treatment variables
Age, gender, relationship status, employment status, and 
primary treatment type were recorded at diagnosis. Patients 
were asked if they had health problems (co-morbidities) 
unrelated to their eye. Largest basal tumor diameter and 
tumor thickness were measured in millimeters. Chromo-
somal mutation M3 is deletion of one of the normal two 
maternal or paternal copies of chromosome 3; disomy 3 (D3) 
is the normal two chromosomes. M3 ten-year disease spe-
cific mortality is over 50% (if tumor diameter is > 12 mm), 
whilst the D3 mortality rate is normal. At the time of this 
study, only liver resection could prolong life for metastatic 
uveal melanoma patients, and only for a small minority. Out-
comes of prognostic testing were M3, D3 or unknown, the 
latter comprising patients who did not wish to be tested, 
when tumor characteristics prohibited prognostication or 
whose cytogenetic test failed.
Anxiety and depression
Anxiety and depression were measured using subscales of 
the Hospital Anxiety and Depression Scale (HADS) (Zig-
mond & Snaith, 1983). Each has seven items scored from 
0 to 3 with higher scores signifying greater symptomology 
(range = 0–21). Both subscales predict diagnosed cases with 
good sensitivity and specificity, with clinical cut-off scores 
of eight and above (Vodermaier & Millman, 2011).
Post-treatment visual and ocular symptoms, visual func-
tional limitations and worry about recurrence were measured 
using sub-scales of the European Organisation for Research 
and Treatment for Cancer Ophthalmic Quality of Life3 ques-
tionnaire (EORTC QLQ-OPT 30; Brandberg et al., 2004), 
designed for UM patients and validated in UM samples 
(Chmielowska et al., 2013).
Symptoms
Subscales used in this study were: ocular irritation (6 items, 
e.g., ‘Discharge from the treated eye’, Cronbach alphas; 
6 months 0.70, 12 months 0.73, 24 months 0.77); visual 
impairment (4 items e.g., ‘Were you troubled by any defects 
in side vision’, Alphas; 0.75, 0.73, 0.72); and headache (sin-
gle item ‘Did you have headaches?’). To simplify analysis, 
we used confirmatory factor analysis to test a single latent 
factor model consisting of the subscales. A final single fac-
tor model with fixed error covariances for the above sub-
scales showed satisfactory fit, Χ2(2.65) = 15.87, CFI = 0.98, 
RMSEA = 0.06. For the analyses, we computed a single 
mean of the three subscales that we labelled visual and ocu-
lar symptoms.
Functional impairment
The EORTC QLQ-OPT 30 sub-scale measuring functional 
limitations was also used (5 items, e.g., ‘Difficulty seeing 
steps or pavements?’ Alphas; 0.93, 0.92, 0.92).
Worry about cancer recurrence (WREC)
We used the EORTC QLQ-OPT 30 4-item sub-scale meas-
uring worry about local and secondary cancer recurrence 
(WREC); Alphas; 0.86, 0.82, 0.82). An item on concern 
about loss of the eye was excluded because it was not rel-
evant to enucleated patients. The remaining three items were 
used: ‘Were you worried about your health in the future?’; 
‘Were you worried about the tumor recurring in the treated 
eye?’ and ‘Were you worried about the tumor recurring in 
other areas of your body?’ Response format for all EORTC 
QLQ-OPT 30 items is ‘Not at all’, ‘A little’, ‘Quite a bit’ and 
‘Very much’, scored 1–4, respectively, and all items were 
worded in terms of poorer outcomes.
3 Previous studies use the term QoL for illness-specific measures 
of symptomology such as the EORTC and generic scale such as the 
FACT-G. We use the term QoL to refer to the generic FACT-G sub-
scales, not the EORTC.
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QoL
QoL was assessed using the physical, social/family, emo-
tional and functional well-being subscales of the Functional 
Assessment of Cancer Therapy –General (FACT-G) Scale 
(Cella, et al., 1993; Webster & Yost, 2003). 27 items are 
scored on a 5-point Likert scale, indicating general health, 
anchored by the terms ‘not at all’ and ‘very much’. Sub-
scale items include physical well-being (7 items, e.g., ‘I 
am forced to spend time in bed’, Alphas; 0.79, 0.82, 0.83); 
Social/family well-being (7 items, e.g., ‘I get support from 
my friends’, Alphas; 0.82, 0.86, 0.87); emotional well-being 
(6 items, e.g., ‘I am losing hope in the fight against illness); 
and functional well-being (7 items, e.g. ‘I am able to enjoy 
life’). Higher scores indicate greater QoL. All subscales have 
been extensively used in cancer populations and show good 
reliability and validity (Cella, et al., 1993; Webster & Yost, 
2003).
All-cause mortality was ascertained from information 
provided by the England and Wales death registry.
Analysis
As data were sometimes skewed (maximum skew = 2.37), 
we used linear mixed modeling to examine temporal trends 
in predictor variables, treating 6, 12 and 24 month obser-
vations as random observations. Linear mixed models are 
robust against skews of at least 3 (Schielzeth, Dingemanse, 
Nakagowa, et al., 2020). Cox regression was used to esti-
mate the adjusted daily hazard ratio of predictor variables 
(differential likelihood of death per day attributable to the 
predictor variable). SPSS version 27 was used for all proce-
dures. The census period for each participant was from the 
24-month timepoint to a census date of 31 December 2018. 
Initial covariates were age, sex, marital status, employment 
status, tumor diameter and thickness, treatment modality 
and chromosome 3 status (D3, M3, unknown), with those 
not contributing to the overall chi-square or -2log likelihood 
statistic discarded for the final analyses. Predictors were 6, 
12 and 24-month scores on all predictor variables. We used 
single variable and multivariate analyses. Single variable 
analyses establish whether individual PROs at the 6, 12, 
and 24 month steps predict mortality independently of the 
covariates, without including other PROs in the model. Mul-
tivariate analyses include all PROs, and identify prediction 
independently of the covariates and other PROs used in the 
study.
In single variable and multivariate analyses, variables were 
entered hierarchically in four steps: covariates were entered 
at the first step (these were common to all analyses), 6 month 
predictors at the second step, 12 month predictors at the 
third step and 24 month predictors at the fourth. Hierarchical 
entry allows statistical control of variables entered at previ-
ous and current steps. Univariate analyses were conducted by 
entering covariates then single PROs at each step (6, 12 and 
24 months). Multivariate analyses were performed by adding 
all predictors at each step. Results are displayed using adjusted 
hazard ratios and 95% confidence intervals. Parameters are 
presented as they appeared at the step on which they were 
entered, not the final model.
We included all patients if they provided data at the 
6-month timepoint. Replacement values were estimated for 
52 participants who missed the 12 month time point, 93 who 
missed the 24 month time point and 131 who missed both 
timepoints. Additionally, 30 patients were excluded who 
completed 6 and 12-month timepoints but died before the 
24 month timepoint. Replacement was by fully conditional 
specification multiple imputation using linear regression for 
continuously distributed variables. Ten imputations (corre-
sponding to approximately 10% missing data) were based 
on age, gender, tumor diameter and thickness, all predictor 
variables at all timepoints, outcome (survival or death) and 
the baseline hazard function (White & Royston, 2009), with 
pooled data used in analyses.
Results
Table 1 shows demographic and clinical characteristics of 
the 824 patients included in the analyses. Mean age was 
68.94 (SD = 12.39) with approximately equal representa-
tion of males and females. 225 (32.5%) of participants 
had a M3 melanoma. 224 patients (27.18%) died before 
the end of census, of whom 126 were M3. Mean number 
of days until the end of census for survivors was 2721.87 
(SD = 794.34). Mean number of days until death was 
1377.54 (SD = 739.42).
Table 2 shows 6, 12 and 24 month means and SDs for pre-
dictor variables. Population norms are available for anxiety, 
depression and QoL scales. Anxiety and depression mean 
scores on the HADS were similar to Crawford et al’s (2001) 
UK (non-clinical) population norms of 6.14 for anxiety and 
3.68 for depression (n = 1,792). QoL norms are not available 
for the UK, but means were similar to roughly comparable 
Australian general population norms (Janda et al., 2009). 
Visual and ocular symptoms and WREC scores declined 
slightly over two years. Emotional QoL scores increased. 
Appendix 1 shows correlations between predictors.
Predictors of mortality
Control variables
Step 1, consisted of demographic and clinical control vari-
ables. Variables not used, because their inclusion did not 
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contribute to the overall chi-square or -2log likelihood sta-
tistic, were sex, marital status, employment status, treatment, 
tumor thickness and self-reported other health problems. 
The step showed multivariate prediction of mortality; Chi-
sq (9df) of 247.79, and -2log likelihood of 2,587.84. This 
step was used in all single and multiple predictor analyses. 
Greater proportional hazard was associated with increasing 
age (adjusted hazard ratio = 1.03, 95% CI = 1.01, 1.04) and 
tumor diameter  (HR(adj) = 1.21, 95% CI = 1.16, 1.27), but not 
sex  (HR(adj) = 0.86, 95% CI = 0.66, 1.23). Chromosome 3 sta-
tus predicted mortality. Compared to the no prognosis group, 
lower mortality was associated with D3  (HR(adj) = 0.22, 95% 
CI = 0.12, 0.39) but M3 participants did not show greater 
mortality  (HR(adj) = 1.29, 95% CI = 0.90, 2.13). Compared 
to enucleation, lower hazard was associated with being 
treated with proton beam radiotherapy  (HR(adj) = 0.45, 95% 
CI = 0.21, 0.94) and resection  (HR(adj) = 0.30, 95% CI = 0.13, 
0.67). Plaque radiotherapy  (HR(adj) = 0.0.59, 95% CI = 0.27, 
1.31) and other treatment  (HR(adj) = 0.76, 95% CI = 0.30, 
1.92) did not predict mortality.
Steps 2, 3 and 4 consisted of 6, 12 and 24 month pre-
dictors respectively. Table 3 shows hazard ratios and 95% 
confidence intervals of step 2–4 predictors in the univariate 
and multivariate survival analysis.
Single variable analyses
Greater mortality was associated with higher depres-
sion scores  (HR(adj) = 1.06) and lower physical QoL 
 (HR(adj) = 0.96) and functional QoL  (HR(adj) = 0.97) at 
six months, 12  month anxiety  (HR(adj) = 1.08) and vis-
ual function limitation scores  (HR(adj) = 1.36), and lower 
12  month physical  (HR(adj) = 0.92) and functional QoL 
 (HR(adj) = 0.968). Visual and ocular symptoms and worries 
about recurrence did not predict mortality.
Multivariate analyses
Significant multivariate increases in prediction occurred 
at 6 (Chi-sq change (7 df) = 27.13, p < 0.01), and 12 month 












Plaque radiotherapy 304 43.9%




Monosomy 3 225 33.5





Tumor diameter (mm) Mean = 11.85 SD = 3.89
Tumor thickness (mm) Mean = 4.46 SD = 3.37
Table 2  Means, SDs and Linear Trends of Predictor variables
* Patients with scores of 8 or greater on HADS anxiety and depression indicating clinical concern (Vodermaier & Millman, 2011). $F statistic 
derived from linear mixed modeling
6 Month 12 Month 24 Month F(2,1459)$
Anxiety 5.48 (4.24) 5.17 (4.14) 5.16 (3.96) 1.45, p = .234
Depression 3.46 (3.47) 3.30 (3.43) 3.28 (3.35) 0.62, p = .536
Anxiety % clinical concern* 29.0 24.2 24.6
Depression % clinical concern 13.8 11.8 12.5
Visual and ocular symptoms 1.59 (0.50) 1.53 (0.42) 1.50 (0.42) 7.03, p < .01
Visual function limitations 1.66 (0.74) 1.62 (0.67) 1.60 (0.61) 1.27, p = .279
Worry cancer recurrence 2.44 (.92) 2.21 (0.80) 2.11 (0.74) 30.58, p < .01
FACT G physical 24.88 (3.89) 24.96 (4.13) 25.20 (3.74) 1.43, p = .239
FACT G social 23.17 (5.57) 23.04 (5.73) 23.02 (5.26) 0.25, p = .861
FACT G emotional 18.40 (4.60) 18.99 (4.30) 19.25 (3.88) 7.82, p < .01
FACT G functional 21.17 (6.23) 21.55 (6.23) 21.84 (5.23) 2.60, p = .074
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steps (Chi-sq change (7 df) = 23.61, p < 0.01) but not the 
24 month step (Chi-sq change (7 df) = 12.96, p = 0.105). Of 
the predictor variables, six-month depression  (HR(adj) = 1.09) 
predicted greater mortality, as lower physical QoL at 12 
 (HR(adj) = 0.93) and 24 months  (HR(adj) = 0.94). Lower anx-
iety at 6 months inversely predicted mortality, but as the 
univariate analysis did not show prediction, this is probably 
attributable to a multivariate suppression effect.4 Neither 
visual and ocular symptoms, visual function limitations nor 
worry about cancer recurrence predicted mortality.
Discussion
We examined PROs as predictors of mortality using three 
methodological improvements over previous studies; 
stronger prognostic control variables, multivariate analy-
ses to identify independent predictors and longitudinal 
assessment of predictors. All variables used have predicted 
mortality in previous studies (Nakaya, 2014; McFarland, 
et al., 2020; Kim, et al., 2014; Efficace, et al., 2021; Wang, 
et al., 2020) but few did so in this study, possibly due to our 
enhanced statistical controls. The univariate analysis showed 
that greater anxiety, depression, visual function limitations 
and poorer functional and physical QoL predicted mortal-
ity. The multivariate analysis showed that depression and 
physical QoL independently predicted mortality. Longitudi-
nal analyses showed the importance of events that occurred 
during survivorship. Mortality was predicted by 12 and 
24 month physical QoL (multivariate), and 6–12 month 
increases in anxiety (univariate only) and decreases in func-
tional QoL (univariate only), suggesting that reductions in 
QoL and increases in anxiety during the study predicted 
mortality.
As mentioned, a key finding is that most PROs did not 
predict mortality after our stringent protections against con-
founding. Neither visual and ocular symptoms, worry about 
cancer recurrence, nor social or emotional QoL predicted 
mortality. We emphasize that this finding does not necessar-
ily constitute a failure to replicate previous studies, because 
we did not use exactly the same PRO measures or the same 
populations. Thus, we cannot definitively claim that previ-
ous findings would not hypothetically survive the enhanced 
statistical controls we used. Nonetheless, in the context of 
our findings, these variables are not yet established to be 
good predictors of mortality.
An exception is our finding that initial depression scores 
predicted mortality. This is commonly found in the literature 
(Pinquart & Duberstein, 2010a; Wang, et al., 2020), and our 
additional control variables lend confidence that the effect is 
Table 3  Univariate and Multivariate Hazard Ratios and 95% Confidence Intervals (smaller font) in Survival Analyses
Full parameters for all models are available in Appendix 2. Parameters are presented as they appeared after the step, not in the final model; Step 
1 control variables were identical for each analysis (see text for parameters); †Single variable analyses are measures of a single predictor at 6, 12 
and 24 month steps, multivariate is the entry of all predictors at each step; * p < .05
Single variable  analyses†
6 Mths. (Step 2) 12 Mths. (Step 3) 24 Mths. (Step 4)
Anxiety 0.96 1.00 1.03 1.021 1.08* 1.14 0.93 0.99 1.06
Depression 1.02 1.06* 1.11 0.99 1.05 1.12 0.96 1.031 1.11
Visual & ocular symptoms 0.891 1.24 1.72 0.83 1.36 2.22 0.47 0.816 1.38
Visual function limitations 0.82 1.01 1.24 1.02 1.36* 1.83 0.53 0.74 1.04
Multivariate  analyses†
6 Mths. (Step 2) 12 Mths. (Step 3) 24 Mths. (Step 4)
Anxiety 0.86 0.90* 0.96 0.93 1.01 1.09 0.92 0.98 1.06
Depression 1.01 1.09* 1.17 0.85 0.93 1.01 0.92 0.98 1.06
Visual & ocular symptoms 0.63 0.98 1.51 0.44 079 1.41 0.42 0.99 1.69
Visual function limitations 0.86 1.10 1.40 0.80 1.13 1.60 0.55 0.88 1.16
Worry cancer recurrence 0.77 0.92 1.13 0.65 0.86 1.13 0.75 1.02 1.38
FACT G physical 0.95 0.98 1.05 0.88 0.93* 0.98 0.89 0.94* 0.98
FACT G social 0.95 0.97 1.00 0.99 1.03 1.07 0.97 1.01 1.04
FACT G emotional 0.92 0.96 1.01 0.89 0.95 1.01 0.97 1.03 1.10
FACT G functional 0.97 1.01 1.04 0.93 0.97 1.01 0.93 0.96 1.01
4 Anxiety and depression scores were correlated (r between .62 and 
.65). Conducting the analysis without anxiety, depression remained a 
predictor. Conducting the analysis without depression scores led to a 
positive but non-significant relationship between anxiety and mortal-
ity, supporting a suppressor effect interpretation.
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probably not attributable to confounding. It is notable that 
changes in depression after the six-month time point did not 
influence mortality. This suggests that mortality might be 
influenced by depressive symptoms manifest either early in 
cancer survivorship or before diagnosis, and that subsequent 
reductions in these are not associated with lower mortality.
Consistent with some previous studies (Groenvold, et al., 
2007; Ratjen, et al., 2018), higher QoL may be protective 
against mortality in cancer patients. Six-month QoL scores 
generally were not associated with mortality (with the 
exception of functional well-being in the univariate analy-
sis). However, relative reductions in physical QoL between 6 
and 12 months predicted higher mortality in the multivariate 
analysis and functional QoL between 6 and 12 months in 
the univariate analysis. Social and emotional QoL did not 
predict mortality. It is notable that QoL domains pertaining 
to physical health and functioning predicted mortality, but 
social and emotional domains did not. It is possible that 
poorer perceptions of health and functioning may represent 
psychological influences on mortality; whereby physical and 
functional QoL represent physically-felt manifestations of 
unknown psychological origins. However, it is also possible 
that poorer physical QoL reflects poorer physical health that 
preceded either metastasis or an unrelated disease that con-
tributed to death. If the latter is true, PROs may not cause 
physical disease, but be useful screening tools to provide 
early indications of it.
Six to twelve-month increases in anxiety and visual func-
tion limitations and 6 month functional QoL were univariate 
but not multivariate predictors. This finding is similar to 
some previous research. Anxiety, for example, has previ-
ously been associated with mortality (Wang, et al., 2020) but 
does not predict mortality independently of depression (see 
also Walker, et al., 2020). In sharing predictive variance with 
other PROs these variables may possibly have a causal role, 
but evidence is not as strong as for independent predictors.
We did not show univariate links between mortality 
and our participants’ concerns about ocular symptoms and 
worry about recurrence. This is possibly because our control 
variables enabled a stricter hypothesis test (Kim et al. and 
McFarland et al. used disease subtype, site, stage and treat-
ment). These variables may not be good predictors of mor-
tality. We concede that our findings could be specific to UM, 
where illness and treatment effects are not as severe as other 
cancers. Patients do not undergo prolonged chemotherapy 
or radiotherapy and symptoms and functional problems are 
constrained to the eye and sight. These PROs may predict 
mortality in cancers where illness and treatment effects are 
more severe. WREC may not be predictive in our study 
because we controlled for M3 status, an objective measure 
of recurrence risk that is known to participants.
Limitations
Although we took precautions against confounding, we 
cannot fully eliminate the possibility that unmeasured bio-
medical variables, associated with either UM or unrelated 
illnesses, explain our findings. We did not examine social 
support, a known predictor of mortality (Pinquart & Duber-
stein, 2010b; Uchino, 2006), because it is not a disease or 
treatment outcome. Nonetheless social support might mod-
erate our findings by reducing negative impacts of depres-
sion. Our linkage to the England and Wales death records 
limits ascertainment of death to residents only, and deaths 
outside this jurisdiction were not recorded.
Research and clinical implications
The most widely cited mechanism for links between PROs 
and mortality is the deleterious influence of physiological 
stress, caused by PROs such as depression, on HPA and 
immune function (Pinquart & Duberstein, 2010a), thus 
accelerating metastatic spread. Depression and poorer QoL 
are associated with HPA and immune dysregulation (Spiegel 
& Giese-Davis, 2003; Wang, et al., 2020). As with most 
previous studies, we cannot eliminate the possibility that 
behavioral risk factors, such as non-compliance with medi-
cations or substance use, linked to depression might be the 
proximal causes of mortality. However, mediation by nei-
ther physiological stress nor health behavior has not been 
formally tested in the literature. To form stronger conclu-
sions about mechanisms, future research, should examine 
mediational hypotheses regarding physiological stress and 
health behavior.
We can point to two clinical insights. Firstly, the timing of 
effects appears to be important. If depression does influence 
mortality, our findings suggest that this effect would prob-
ably be established by the first six months of survivorship. 
Depression reductions after this point were not associated 
with improved mortality, suggesting that any interventions 
should be delivered early in survivorship. Conversely, QoL 
changes after six months were predictive, thus identifying 
the reasons for relative decline in QoL, and possibly anxi-
ety, after six months could be important for intervention. If 
declines in physical QoL represent somatization of psycho-
logical distress leading to mortality, distress could poten-
tially be identified and treated. If it provides early indication 
of disease progression, there may be diagnostic implications.
Second, overall depression and anxiety scores were com-
parable to community norms (Crawford, et al., 2001). This 
suggests that variations in anxiety and depression within 
normal population parameters are potentially important 
in predicting mortality. Psychological services for can-
cer patients have traditionally focused on clinical and 
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sub-clinical groups, although there is some evidence in can-
cer generally (Bonacchi, et al., 2010) and UM in particular 
that psychological need is present in patients who do not 
meet clinical thresholds (Hope-Stone et al., 2019). Our find-
ings suggest that recent developments in widening popula-
tion access through accessible but effective interventions, 
such as online psychological self-help programmes (White, 
et al., 2020), may be helpful.
Overall, this study provided only limited support for the 
proposal that PROs are associated with mortality, with only 
depression and physical QoL being significant multivariate 
predictors. Causality could be established by research, that 
elucidates mediation of this effect, and shows that reducing 
depression and increasing physical QoL can improve mortal-
ity. Such research could underpin interventions that might 
improve mortality.
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